Wellinks Raises $10M Series B to Scale Predictive Cardiopulmonary Remote Patient Monitoring Into Rural Markets

Wellinks, a New Haven, Connecticut-based digital health company focused on cardiopulmonary care, raised $10 million in the first close of its Series B financing from UMass Memorial Health and inside investors. The round was announced August 4, 2026, and brings Wellinks' total funding to approximately $43 million. The capital will fund commercial expansion into rural and underserved markets, advance the company's predictive analytics engine, and extend the care model from its core COPD focus into congestive heart failure.

What Wellinks Builds

Wellinks provides a virtual care platform for patients with chronic obstructive pulmonary disease and congestive heart failure, two of the most common and costly chronic conditions in the United States. COPD affects approximately 16 million Americans who are diagnosed, with an estimated additional 12 million who have the disease but are undiagnosed. CHF affects approximately 6.5 million Americans. Together, the two conditions are leading drivers of hospital readmissions, emergency department utilisation, and healthcare spending.

Wellinks' FDA-cleared Spire Remote Patient Monitoring System collects physiological data from COPD and CHF patients at home and uses predictive algorithms to identify early signs of clinical deterioration before they progress to acute exacerbations that require hospitalisation. Clinicians receive alerts when a patient's data pattern crosses threshold indicators for potential deterioration, allowing intervention through a phone call, medication adjustment, or home visit rather than waiting until the patient presents at an emergency department.

A clinical study of Wellinks' platform found that participants had more than 60% lower odds of hospital readmission within 30 days compared to similar patients who did not participate. The reduction in 30-day readmissions is a critical metric in the current US healthcare reimbursement environment, where hospitals face financial penalties under the Hospital Readmissions Reduction Program for excess readmissions in conditions including COPD and heart failure. Wellinks' platform reduces both the clinical and financial burden of readmissions for its health system partners.

UMass Memorial Health as Strategic Investor

The participation of UMass Memorial Health as a strategic investor, rather than just a customer, is the most notable structural feature of this round. UMass Memorial is the largest health system in central Massachusetts and one of the major academic medical centres in New England. When a health system invests in a digital health company rather than simply piloting or subscribing to its platform, it signals clinical validation and a deeper operational integration that is difficult for competing platforms to replicate. The strategic investment also likely comes with patient cohort access and real-world outcomes data that strengthens Wellinks' clinical evidence base.

For founders building in chronic disease management or remote patient monitoring, the UMass investment structure is a model worth understanding. Health system strategic investments create durable competitive moats: they provide revenue, clinical credibility, outcomes data, and a reference customer simultaneously. Finding a health system willing to invest rather than just purchase requires a platform with proven clinical efficacy, but the competitive advantage it creates is substantial. See active digital health and medtech investors on AngelLinx for the broader investor landscape.

What This Means for Founders

Wellinks' $10 million Series B first close demonstrates that investors in digital health are still writing checks for companies with strong clinical evidence and a clear path to reducing healthcare costs. The 60% reduction in 30-day readmissions is the kind of clinical outcome that health system buyers, payers, and investors can all agree is worth paying for. For founders in digital health, understanding your annual recurring revenue per patient or per health system contract and your runway to the next clinical proof point are the two most important financial metrics for a Series B conversation in this category. Use the investor match tool to find digital health investors with experience in chronic disease, remote monitoring, and rural health access.

Digital health founders building in cardiopulmonary care, chronic disease management, or rural health can explore investors on AngelLinx @ angellinx.ai/register.

AngelLinx Intelligence | angellinx.ai